Brought to you by 
DelMar Pharmaceuticals raises $5.4mm through private placement post-reverse merger; now totals $10.5mm
18 Mar 2013
Executive Summary
Concurrent with the closing of a reverse merger in which it became public, cancer therapeutics developer DelMar Pharmaceuticals Inc. raised $5.4mm through the first closing of a private placement in which it sold 6.7mm common shares at $0.80 apiece to accredited investors. Buyers also received five-year warrants to purchase 6.7mm additional shares at $0.80. Charles Vista was appointed the placement agent for this and future closings. Proceeds will go towards trials of DelMar’s glioblastoma multiforme candidate VAL083.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Private Investment in Public Equity
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
DelMar Pharmaceuticals raises $5.4mm through private placement post-reverse merger; now totals $10.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice